Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534738 | 0.92 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL21886137 | 0.92 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL7480702 | 0.91 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL7475973 | 0.90 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL7483912 | 0.89 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL8194048 | 0.87 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL21886412 | 0.87 | CRHR1 (0.60) | CRHR1 | |
| SCHEMBL7538831 | 0.84 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL8202582 | 0.81 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL21886149 | 0.81 | CRHR1 (0.58) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844071-B2 | Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200190094-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRIMIDINES THAT LOWER STRESS-INDUCED P-TAU | BUCK INSTITUTE FOR RESEARCH ON AGING | 2020-06-18 | — | — | US | disclosed |
| US-10618899-B2 | Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2020-04-14 | — | — | US | disclosed |
| US-6107300-A | CORTICOTROPIN RELEASING FACTOR ANTAGONIST; PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844071-B2 | Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau | MAPT, PSEN1, PSEN2 | CRHR1 36/4885 |
| US-20200190094-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRIMIDINES THAT LOWER STRESS-INDUCED P-TAU | MAPT, PYGB, PSEN1 | CRHR1 92/4885 |
| US-10618899-B2 | Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau | MAPT, PSEN1, PSEN2 | CRHR1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.